With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A new study has used powerful imaging to reveal a subset of Alzheimer's-associated proteins spreading particularly rapidly.

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

A rapid screening method developed using C. elegans to identify compounds that suppress disease-causing amyloids linked to ...

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...